<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[healthcare and research recap Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/healthcare+and+research+recap.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to healthcare and research recap]]></description>
	<s:counts start="0" returned="5" found="5" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Medical Costs of Obesity Double in Last 10 Years]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F151781-medical-costs-of-obesity-double-in-last-10-years%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Research Recap submits:   Yet another reason why health care reform is critical to the nation&#8217;s economic prosperity as well as its wellbeing: the medical costs of obesity are estimated to have doubled in the last 10 years, with as much as half of the cost covered by Medicare...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 28 Jul 2009 04:13:53 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/research+recap.html"><![CDATA[Research Recap]]></category>
	</item>
	<item>
		<title><![CDATA[Boston Scientific Poised to Attain Investment Grade Rating]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F149255-boston-scientific-poised-to-attain-investment-grade-rating%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Research Recap submits:   Boston Scientific BSX is poised to gain an investment grade credit rating,  according to Standard & Poor&#8217;s latest list of potential &#8220;rising stars.&#8221;   All entities that were on S&P&#8217;s list in June remain potential rising stars this month, with the addition of...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 16 Jul 2009 08:54:51 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/research+recap.html"><![CDATA[Research Recap]]></category>
		<category domain="http://resources.bnet.com/topic/boston+scientific+corp..html"><![CDATA[Boston Scientific Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BSX</category>
		<category domain="tickers">BSX</category>
	</item>
	<item>
		<title><![CDATA[Global Pharma Outlook Negative as Patents Expire]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F144075-global-pharma-outlook-negative-as-patents-expire%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Research Recap submits:   The outlook for the global pharmaceutical industry remains negative, mainly due to looming patent expirations of top-selling drugs and weakening product pipelines, says Moody&#8217;s in a new Global Pharmaceutical  Industry Outlook. Key points: Consolidation in the form of M&A or diversification into other health-related...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 18 Jun 2009 12:43:01 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/research+recap.html"><![CDATA[Research Recap]]></category>
		<category domain="http://resources.bnet.com/topic/astrazeneca+plc..html"><![CDATA[AstraZeneca Plc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
		<category domain="tickers">AZN</category>
	</item>
	<item>
		<title><![CDATA[New Drug Approvals on Pace to Exceed 2008 Total]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F142458-new-drug-approvals-on-pace-to-exceed-2008-total%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Research Recap submits:   Over the next two quarters as many as eight highly-promising new drug candidates may be successfully commercialized despite higher hurdles at government drug regulatory agencies, according to Fitch Ratings.   In its quarterly global pharmaceutical report, Fitch says the total amount of marketing clearances...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 10 Jun 2009 08:04:18 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/research+recap.html"><![CDATA[Research Recap]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="tickers">GSK</category>
	</item>
	<item>
		<title><![CDATA['Indian Pharma' Industry Poised for Strong Growth]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F133363-indian-pharma-industry-poised-for-strong-growth%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Research Recap submits:   Indian pharmaceutical firms are defying a broad-based slowdown in Indian exports, and are poised for strong growth, according to Oxford Analytica. Growing demand for cheap, generic drugs is proving a particular boon, reflected in a 46% year-on-year rise in exports to the United States during...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 27 Apr 2009 10:18:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/research+recap.html"><![CDATA[Research Recap]]></category>
	</item>
</channel>
</rss>
